New crystal form of small-particle-size azilsartan and preparation method thereof
By adding water in a good solvent, the problems of poor thermal stability and crystallization versatility of azisartan were solved, and a new crystal form with a particle size less than 2μm was prepared, which improved the bioavailability of azisartan and Stability, simplifies process and reduces costs.
Patent Information
- Application Number
- CN202410989654.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The thermal stability of azisartan leads to a decrease in purity during the crushing process. The existing small-particle preparation method is complex in operation, high in cost and difficult to industrially produce, and the drug has crystalline pleomorphism that affects bioavailability and stability.
The preparation method of dissolving azisartan in a good solvent and adding it backdrop to water, beating and drying, control the dissolution temperature, dropping time and water ratio, ensure that the particle size is less than 2μm, improve the dissolution rate and dissolution degree, and prepare new crystals. Type, simple operation, suitable for industrial production.
The high bioavailability, stability and high purity of the new crystal form of azisartan is achieved, the preparation process is simplified, the production cost is reduced, and the dissolution effect and stability of the drug are improved.
Smart Images

Figure CN118908949A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a new small-particle azilsartan crystal form and a preparation method thereof, and belongs to the technical field of drug polymorph preparation. Background Art
[0002] Azilsartan, with the chemical name 1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl-2-ethoxy-1H-benzimidazole-7-carboxylic acid, has a structural formula as shown below. Azilsartan is an angiotensin II receptor antagonist drug developed by Takeda Pharmaceuticals of Japan for the treatment of hypertension. It selectively blocks the binding of angiotensin II to the AT1 receptor of vascular smooth muscle and thus blocks the contraction of blood vessels, thereby producing a hypotensive effect. It has significant clinical efficacy and has very good market application prospects.
[0003]
[0004] Azilsartan is a drug belonging to BCS Class IV (low solubility and low permeability), and its dissolution is the rate-limiting step that affects drug absorption, thereby affecting the bioavailability of the drug. In order to improve the dissolution behavior of poorly soluble solid preparations, the dissolution rate and solubility can be increased by using small-particle APIs. At present, there are two methods for preparing small-particle APIs: crushing and crystallization. However, due to the poor thermal stability of azilsartan, the heat generated during the crushing process can cause its purity to decrease and impurities to exceed the standard. In order to avoid the problem of reduced purity of azilsartan API due to thermal degradation, patent CN103831195A uses a mixture of liquid nitrogen and azilsartan to consume the heat generated during the crushing process, but this method has strict requirements on operating conditions, high cost, and is not convenient for industrial scale-up production. Therefore, the use of crystallization to prepare small-particle azilsartan APIs is the best way to avoid the problem of thermal degradation and ensure its purity.
[0005] Patent CN110041320A reports a method of preparing a small particle size sample of Azilsartan Form A by dissolving Azilsartan in a mixed solvent of methanol and water, distilling off part of the solvent, and cooling and crystallizing. The particle size range is 3 μm. <D 50<20 μm; Patent CN113278016A prepares a small particle size sample of azilsartan polymorph A by dropping a dissolved azilsartan solution into a mixed solvent for crystallization, with the particle size range of 3 μm < D50 < 20 μm; Patent CN108774217A adds tetrahydrofuran to azilsartan raw material to form a suspension, and then through solid-liquid separation, washing, and drying processes, a dispersed raw material sample is obtained; acetone is added to the obtained dispersed raw material sample for dissolution, and then part of the acetone is removed; the temperature is lowered for cooling, and finally through solid-liquid separation, washing, and drying processes, a micronized raw material with a particle size range of 3 μm < D 50 <20 μm. The operation procedure is troublesome, and smaller particle size samples cannot be prepared.
[0006] In addition, it is reported that azilsartan has crystalline polymorphs, which refer to multiple crystal forms with different crystalline structures in the same molecule. Each crystal form in the crystalline polymorphs mostly has different characteristics related to the quality of pharmaceuticals, such as appearance, solubility, melting point, dissolution rate, bioavailability, stability, effectiveness, etc. Patent CN103930419A discloses 11 crystal forms of azilsartan, namely A, B, C, D, E, F, G, H, I, J, K. Each crystal form needs to be prepared by different preparation methods. Among them, to prepare crystal form A, azilsartan is dissolved in DMF to form a solution, acetone is added, the temperature is raised to about 60 °C, after filtration with a filter head, water is added dropwise to about 60 °C and cooled to room temperature, the precipitate is filtered, and dried under vacuum at about 50 °C. The obtained dried sample is crystal form A. Patent CN102827153A discloses the crystal form of azilsartan and its preparation method, including dissolving azilsartan in an organic solvent ethanol and crystallizing at room temperature; Patent CN102766139A discloses azilsartan polymorph A in its azilsartan polymorphs and its preparation method. Using azilsartan as the raw material, azilsartan is mixed with a solvent of anhydrous methanol or anhydrous methanol / water, heated to dissolve all azilsartan, and then cooled for crystallization, and the precipitate is filtered and recovered; Patent CN113278016A discloses a preparation method of small particle size azilsartan polymorph A. Azilsartan is dissolved in dimethyl sulfoxide or tetrahydrofuran, filtered; the filtrate is dropped into a mixed solution of a water-soluble organic solvent and water under stirring for crystallization; filtered, washed, and dried to obtain. Summary of the Invention
[0007] In order to improve the bioavailability of azilsartan in vivo and in vitro, improve the dissolution behavior of poorly soluble drug solid preparations, and improve the performance in terms of stability, etc., the present invention makes the following inventions.
[0008] On the one hand, the present invention provides a new crystal form of azilsartan, which has high bioavailability; and / or has good performance in terms of stability, is conducive to storage, and thus meets the requirements of drug stability.
[0009] In some embodiments, the characteristic diffraction peaks (2θ) of the X-ray powder diffraction pattern of the new crystal form of Azilsartan are: 4.6±0.2, 9.2±0.2, 11.0±0.2, 11.9±0.2, 13.9±0.2, 21.1±0.2, 21.5±0.2, 23.9±0.2, 24.5±0.2, 24.9±0.2. For details, see the X-ray powder diffraction characteristic peak data in Table 1 and Figure 1 shown.
[0010]
[0011] On the other hand, the present invention provides a process for preparing a small-particle API of a new crystal form of Azilsartan. The process is simple to operate and has good reproducibility, which is conducive to industrial scale-up production. In addition, compared with the preparation method of patent CN110041320A, the Azilsartan API prepared by the process has higher purity (>99.9%) and smaller particle size (D 50 <2μm), and have a greater dissolution rate and dissolution rate, which may ensure that its preparation has better bioavailability and lower toxic side effects.
[0012] In some embodiments, the preparation method of the small-particle azilsartan new crystal drug substance comprises the following steps: The crude product of Azilsartan is dissolved in a good solvent, and then added dropwise to water. After the addition is completed, the mixture is kept warm for slurrying, filtered, washed with water, and dried. The small particle size sample (such as Figure 2 as shown).
[0013] Preferably, the good solvent for dissolving azilsartan is dimethyl sulfoxide (DMSO), dimethylacetamide (DMAC) and dimethylformamide (DMF); Preferably, the dissolution temperature of crude azilsartan is 20° C.-25° C. The inventors surprisingly found that when the dissolution temperature is higher than 25° C., azilsartan will degrade, resulting in reduced sample purity; when the dissolution temperature is lower than 20° C., the solubility of azilsartan in a good solvent is significantly reduced, resulting in reduced product yield.
[0014] Preferably, the volume of the added good solvent and the mass of the crude azilsartan (v / w) are 1.5-2.0:1; the inventors surprisingly found that when the volume of the good solvent and the mass of the crude azilsartan (v / w) are less than 1.5, there is a risk of solid precipitation in the azilsartan good crude solvent solution during the dropwise addition process; when the volume of the good solvent and the mass of the crude azilsartan (w / v) are greater than 2.0, the product particle size will be significantly increased.
[0015] Preferably, the mass ratio of crude azilsartan to water is 1:20-1:25; the inventors surprisingly found that when the mass ratio of crude azilsartan to water is less than 1:20, the high viscosity of the slurry easily causes product particles to agglomerate, thereby increasing the product particle size; when the mass ratio of crude azilsartan to water is greater than 1:25, there is no obvious change in product quality (particle size, purity, etc.), so from the perspective of environmental protection and cost, there is no need to further increase the amount of water in the process.
[0016] Preferably, the dropping time is 8 hours to 14 hours; the inventors surprisingly found that when the dropping time is less than 8 hours, the product particles will agglomerate and increase their particle size; when the dropping time is greater than 14 hours, the product quality (particle size, purity, etc.) has no obvious change. From the perspective of cost and production capacity, there is no need to further extend the dropping time in the process.
[0017] Preferably, the temperature is maintained at 0°C-5°C during the dropwise addition process; the inventors surprisingly found that when the temperature during the dropwise addition process is greater than 5°C, the product particle size will be significantly increased; when the temperature during the dropwise addition process is less than 0°C, the product quality (particle size, purity, etc.) does not change significantly, and from a cost perspective, there is no need to further reduce the temperature during the dropwise addition process.
[0018] Preferably, the heat preservation and beating time is 16 to 20 hours; Preferably, the drying temperature is less than 35°C.
[0019] The technical solution of the present invention achieves the following technical advantages: 1) It provides a new crystal form for selection, which is basically consistent with the original research in terms of stability and has significantly better dissolution effect than the original research; 2) Provides a small particle size product with a particle size D50 < 2μm, which improves the dissolution effect of the finished drug and is more suitable for the needs of drug preparations; 3) The dissolution temperature during the preparation process is not high, which saves energy and reduces consumption. The operation is simple and more suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the X-ray powder diffraction pattern of the new crystal form of Azilsartan Figure 2 This is the particle size detection spectrum of the new crystal form of Azilsartan Specific implementation measures Instruments and determination methods used in the present invention: 1) X-ray powder diffractometer Model: Shimadzu XRD 6000 X-ray Diffractometer Test method: 100g of ground sample was filled into the groove of the glass plate, and then the sample was placed in Shimadzu XRD 6000 powder diffractometer, using a 40Kv, 40mA copper target X-ray source, a scanning range of 5-40°, a scanning speed of 5° / min, and a test temperature of room temperature.
[0021] 2) Release rate detection method Model: Sotax fully automatic dissolution testing system Test method: Refer to USP dissolution test method, flow cell method, open loop; Dissolution medium: artificial gastric juice and artificial intestinal juice; Temperature: 37.5±0.5℃; Speed: 50rpm; Sampling time: 2h, 4h, 6h, 8h and 10h. Example 1
[0022] 10 g of crude azilsartan and 17 mL of DMSO were added to a 50 mL beaker, stirred at 23 ° C until dissolved, filtered, and the filtrate was slowly added dropwise to a 500 mL reaction bottle containing 220 g of purified water within 8 hours. The temperature was maintained at 3 ° C during the addition. After the addition was completed, the mixture was kept warm and slurried for 17 hours at a speed of 350 rpm, filtered, washed with 30 mL of purified water, and dried at 35 ° C for 12 hours to obtain 8.8 g of white solid powder with a yield of 88.0%, a purity of 99.95%, a main particle size D50 of 1.876 μm, and a particle size detection data of the new crystal form of azilsartan Figure 2 shown.
[0023] The X-ray powder diffraction (X-PRD) spectrum has characteristic peaks at the following 2θ angle positions: 4.6±0.2, 9.2±0.2, 11.0±0.2, 11.9±0.2, 13.9±0.2, 21.1±0.2, 21.5±0.2, 23.9±0.2, 24.5±0.2, 24.9±0.2.
[0024] The specific X-ray powder diffraction spectrum data are as follows:
[0025] Example 2 10 g of crude azilsartan and 15 mL of DMAC were added to a 50 mL beaker, stirred at 20 ° C until dissolved, filtered, and the filtrate was slowly added dropwise to a 500 mL reaction bottle containing 200 g of purified water within 12 hours. The temperature was kept at 0 ° C during the addition. After the addition was completed, the mixture was kept warm and beaten for 19 hours at a speed of 350 rpm, filtered, washed with 20 mL of purified water, and dried at 35 ° C for 16 hours to obtain 9.29 g of white solid powder with a yield of 92.9%, a purity of 99.93%, and a main particle size D50 of 1.856 μm. The XPRD spectrum was determined to be consistent with Figure 1 Basically the same. Example 3
[0026] 10 g of crude azilsartan and 20 mL of DMF were added to a 50 mL beaker, stirred at 25 ° C until dissolved, filtered, and the filtrate was slowly added dropwise to a 500 mL reaction bottle containing 250 g of purified water within 14 hours. The temperature was maintained at 5 ° C during the addition. After the addition was completed, the mixture was kept warm and beaten for 18 hours at a speed of 350 rpm, filtered, washed with 40 mL of purified water, and dried at 35 ° C for 18 hours to obtain 9.08 g of white solid powder with a yield of 90.8%, a purity of 99.92%, and a main particle size D50 of 1.875 μm. The XPRD spectrum was determined to be consistent with Figure 1 Basically the same. Example 4
[0027] 10 g of crude azilsartan and 15 mL of DMSO were added to a 50 mL beaker, stirred at 20 ° C until dissolved, filtered, and the filtrate was slowly added dropwise to a 500 mL reaction bottle containing 200 g of purified water within 8 hours. The temperature was kept at 0 ° C during the addition. After the addition was completed, the mixture was kept warm and pulped for 17 hours at a speed of 350 rpm, filtered, washed with 30 mL of purified water, and dried at 35 ° C for 12 hours to obtain 9.42 g of white solid powder with a yield of 94.2%, a purity of 99.96%, and a main particle size D50 of 1.881 μm. The XPRD spectrum was determined to be consistent with Figure 1 Basically the same. Example 5
[0028] 10 g of crude azilsartan and 20 mL of DMAC were added to a 50 mL beaker, stirred at 25 ° C until dissolved, filtered, and the filtrate was slowly added dropwise to a 500 mL reaction bottle containing 200 g of purified water within 12 hours. The temperature was kept at 0 ° C during the addition. After the addition was completed, the mixture was kept warm and beaten for 19 hours at a speed of 350 rpm, filtered, washed with 20 mL of purified water, and dried at 35 ° C for 16 hours to obtain 9.09 g of white solid powder with a yield of 90.9%, a purity of 99.94%, and a main particle size D50 of 1.871 μm. The XPRD spectrum was determined to be consistent with Figure 1 Basically the same. Example 6
[0029] 10 g of crude azilsartan and 15 mL of DMF were added to a 50 mL beaker, stirred at 20 ° C until dissolved, filtered, and the filtrate was slowly added dropwise to a 500 mL reaction bottle containing 200 g of purified water within 10 hours. The temperature was maintained at 5 ° C during the addition. After the addition was completed, the mixture was kept warm and beaten for 18 hours at a speed of 350 rpm, filtered, washed with 40 mL of purified water, and dried at 35 ° C for 18 hours to obtain 9.12 g of white solid powder with a yield of 91.2%, a purity of 99.90%, and a main particle size D50 of 1.865 μm. The XPRD spectrum was determined to be consistent with Figure 1 Basically the same. Comparative Example 1
[0030] Referring to patent CN110041320A, 500g of methanol and 50g of purified water were added to a 1000mL reaction bottle, the temperature was stirred and heated to 50°C-60°C, 10g of crude azilsartan was added, the mixture was kept warm and stirred for 20 minutes, filtered, the stirring speed was controlled to 400 rpm, and about 60g of solvent was evaporated under reduced pressure at a water bath temperature of 60°C-70°C. The reaction bottle was placed in an ultrasonic water bath, 200g of ice water was added to the reaction bottle, the temperature was lowered to 0°C-5°C, the temperature was kept warm for 10 minutes, filtered, and vacuum dried at 45°C to obtain 8.1g of white solid powder with a yield of 81%, a purity of 99.89%, and a main particle size D50 of 7.3μm. After measurement, the solid form was Form A. Comparative Example 2
[0031] Referring to patent CN113278016A, 15g of crude azilsartan and 90mL of tetrahydrofuran were added to a 250mL beaker, stirred at room temperature to dissolve, and filtered. The filtrate was added dropwise to 900mL of a methanol-water mixed solvent (100:800, V / V) at room temperature at a speed of 160 rpm. After the addition was completed, the mixture was filtered and dried at 45°C to obtain 14.0g of a white solid powder with a yield of 93.6%, a purity of 99.73%, and a main particle size D50 of 2.38μm. After determination, the solid form was crystal form A. Dissolution test
[0032] The azilsartan raw materials prepared in Example 1, Example 2 and Example 3 and the azilsartan raw material prepared in Comparative Example 1 were respectively prepared into tablets according to patent CN116421571A, and their dissolution was investigated using a circulation cell, wherein the dissolution medium was artificial gastric juice and artificial intestinal juice, the rotation speed was 50 rpm, and the temperature was 37±0.5°C. The experimental results are shown in Table 2.
[0033]
[0034] It can be seen from the above experimental results that compared with the azilsartan API prepared in Comparative Examples 1 and 2, the azilsartan API prepared in Examples 1, 2 and 3 has a faster dissolution rate and a greater solubility, thereby being able to effectively improve the bioavailability of the azilsartan preparation and reduce its toxic side effects. Stability test
[0035] The prepared azilsartan samples of Example 1, Example 2, Example 3, Comparative Example 1 and Comparative Example 2 were respectively placed under high temperature (60°C), high humidity (75%RH) and light (5000±500lux) conditions to investigate their stability for 30 days. The experimental results are shown in Table 3.
[0036]
[0037] It can be seen from the above experimental results that, compared with the azilsartan samples prepared in Comparative Examples 1 and 2, under high temperature and high humidity conditions, the azilsartan samples prepared in Example 1, Example 2 and Example 3 all have good physicochemical stability.
Claims
1. A new crystal form of small-particle azilsartan, characterized in that Using Cu-Kα radiation, the X-ray powder diffraction (X-PRD) pattern has characteristic peaks at the following 2θ angle positions: 4.6±0.2, 9.2±0.2, 11.0±0.2, 11.9±0.2, 13.9±0.2, 21.1±0.2, 21.5±0.2, 23.9±0.2, 24.5±0.2, 24.9±0.
2.
2. The new crystal form according to claim 1, characterized in that The X-ray powder diffraction (X-PRD) pattern is shown in FIG1 .
3. The new crystal form according to claim 1, characterized in that The small particle size is D50<2 μm.
4. A method for preparing a new crystal form of small-particle azilsartan, characterized in that The crude product of Azilsartan is dissolved in a good solvent, and then added dropwise into water. After the addition is completed, the mixture is kept warm for slurrying, filtered, washed with water, dried, and collected to obtain a small particle size sample.
5. The preparation method according to claim 4, characterized in that The benign solvent is any one of dimethyl sulfoxide (DMSO), dimethylacetamide (DMAC) and dimethylformamide (DMF).
6. The preparation method according to claim 4, characterized in that The crude azilsartan is dissolved in a good solvent at a dissolving temperature of 20°C-25°C.
7. The preparation method according to claim 4, characterized in that The volume of the added good solvent and the mass of the crude azilsartan are (1.5-2.0):
1.
8. The preparation method according to claim 4, characterized in that The mass ratio of the added crude azilsartan to water is 1:20-1:
25.
9. The preparation method according to claim 4, characterized in that The dropping time is 8 to 14 hours.
10. The preparation method according to claim 4, characterized in that During the dropping process, the temperature is maintained at 0°C-5°C.
Citation Information
Patent Citations
Preparation method of crystals of azilsartan
CN110041320A
Preparation method of small-particle-size azilsartan
CN113278016A
Manufacturing method of azilsartan fine crystal
JP2019172635A
Cited By
Preparation method of small-particle-size alprazolam crystal form I
CN120590395A
